A Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia - SAPPHIRE

Study identifier:D5495C00002

ClinicalTrials.gov identifier:NCT03990363

EudraCT identifier:2018-004079-11

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic KIdney Disease and Hyperuricaemia

Medical condition

Chronic Kidney Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol

Sex

All

Actual Enrollment

861

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 23 Jul 2019
Primary Completion Date: 22 Nov 2021
Study Completion Date: 22 Nov 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria